{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:47Z","timestamp":1787771867895,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Most of the predictive tools put up to prognosticate treatment outcomes in patients with chronic lymphocytic leukaemia (CLL) are not easily available and affordable in our resource-constrained environment.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n The aim of this study was to evaluate the impact of staging and some tumour bulk on treatment outcomes of persons with CLL, Enugu, Nigeria.<\/jats:p>\n <\/jats:sec>\n \n Patients and Methods:<\/jats:title>\n This is a 10-year review of the CLL data from the haemato-oncology unit of a Nigerian tertiary hospital to evaluate the impact of staging and tumour bulk indicators. Data were retrieved from the case notes of 102 patients with CLL receiving care at the facility. Data of interest include basic demographic variables, clinical features including spleen size and disease staging and blood counts. Statistical analysis was done using SPSS version 22.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The median absolute lymphocyte count (ALC) was 108.05 (confidence interval [CI] = 50.8\u2013201.3, interquartile range [IQR] = 124.4) \u00d7109\/L, and duration of survival for the study cohort was 5.5 (CI = 3.5\u201331.9, IQR = 27) months. Majority (69, 79.3%) were in Stage C. The Binet stage showed a significant association with the ALC (\n r<\/jats:italic>\n = 0.338;\n P<\/jats:italic>\n = 0.002) but not with spleen size (\n r<\/jats:italic>\n = 0.198;\n P<\/jats:italic>\n = 0.056). The duration of survival only showed a significant inverse relationship with the ALC (\n r<\/jats:italic>\n = 0.35,\n P<\/jats:italic>\n = 0.006) but with neither the Binet stage (\n r<\/jats:italic>\n = 0.103,\n P<\/jats:italic>\n = 0.431) nor spleen size (\n r<\/jats:italic>\n = 0.184,\n P<\/jats:italic>\n = 0.116).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n In CLL patients, ALC at presentation correlates with the duration of survival. We recommend that the ALC at presentation be used as a prognostic marker in our clime.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/npmj.npmj_246_23","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T02:02:02Z","timestamp":1707271322000},"page":"76-80","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Binet Staging versus Tumour Bulk on Treatment Outcome in Chronic Lymphocytic Leukaemia"],"prefix":"10.4103","volume":"31","author":[{"given":"Anazoeze Jude","family":"Madu","sequence":"first","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"},{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Chioma","family":"Okoye","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"},{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebele Adaobi","family":"Muoghalu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Ogechukwu","family":"Ugwu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"},{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine Nwakuche","family":"Duru","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"},{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Emeka","family":"Nonyelu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"},{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikechukwu Okwudili","family":"Anigbogu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"},{"name":"Department of Haematology and Immunology, University of Nigeria, Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinedu Anthony","family":"Ezekekwu","sequence":"additional","affiliation":[{"name":"Department of Haematology and Immunology, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"R1-20240908","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2010","journal-title":"Blood"},{"key":"R2-20240908","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type:A report from the haematological malignancy research network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"R3-20240908","first-page":"1","article-title":"Pattern of haematological malignancies in Ilorin, Nigeria:A ten-year review","volume":"5","author":"Babatunde","year":"2008","journal-title":"Int J Hematol"},{"key":"R4-20240908","first-page":"1","article-title":"Epidemiological pattern of adult haematological malignancies in a tertiary hospital in cross river state","volume":"2","author":"Akaba","year":"2019","journal-title":"Int Res J Oncol"},{"key":"R5-20240908","first-page":"1094","article-title":"Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease-progression on overall survival","volume":"84","author":"Molica","year":"1999","journal-title":"Haematologica"},{"key":"R6-20240908","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/asheducation-2010.1.77","article-title":"Prognostic markers and stratification of chronic lymphocytic leukemia","volume":"2010","author":"Furman","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R7-20240908","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1002\/cncr.32353","article-title":"Predicting the outcome of patients with chronic lymphocytic leukemia:Progress and uncertainty","volume":"125","author":"Montserrat","year":"2019","journal-title":"Cancer"},{"key":"R8-20240908","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","article-title":"Growth dynamics in naturally progressing chronic lymphocytic leukaemia","volume":"570","author":"Gruber","year":"2019","journal-title":"Nature"},{"key":"R9-20240908","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1073\/pnas.1409362111","article-title":"Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)","volume":"111","author":"Komarova","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R10-20240908","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/bloodadvances.2019000367","article-title":"Clonal dynamics in chronic lymphocytic leukaemia","volume":"3","author":"Gutierrez","year":"2019","journal-title":"Blood Advances"},{"key":"R11-20240908","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI):A meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"R12-20240908","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2016-07-728261","article-title":"Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients","volume":"128","author":"Gentile","year":"2016","journal-title":"Blood"},{"key":"R13-20240908","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"key":"R14-20240908","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"Aclinical staging system for chronic lymphocytic leukemia:Prognostic significance","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"R15-20240908","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/cncr.28233","article-title":"Racial differences in chronic lymphocytic leukemia. Digging deeper","volume":"119","author":"Flowers","year":"2013","journal-title":"Cancer"},{"key":"R16-20240908","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/10428194.2019.1680840","article-title":"Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017","volume":"61","author":"Weide","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R17-20240908","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/GO.20.00276","article-title":"Chronic lymphocytic leukemia:Prognostic factors at presentation in a resource-limited center","volume":"7","author":"Korubo","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"R18-20240908","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2008.07086.x","article-title":"The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"141","author":"Zent","year":"2008","journal-title":"Br J Haematol"},{"key":"R19-20240908","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia:Natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"R20-20240908","first-page":"92","article-title":"Early intervention in asymptomatic chronic lymphocytic leukemia","volume":"19","author":"Muchtar","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"R21-20240908","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1080\/10428190600881322","article-title":"Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study","volume":"47","author":"Apelgren","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R22-20240908","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/ijh.ijh_23_21","article-title":"The significan of Rai and Binet clinical staging on the survival of chronic lymphocytic leukemia patients in the Kurdistan region of Iraq","volume":"10","author":"Muhammad","year":"2021","journal-title":"Iraqi J Hematol"},{"key":"R23-20240908","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda","year":"2011","journal-title":"J Clin Oncol"},{"key":"R24-20240908","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4314\/mmj.v31i2.7","article-title":"Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria","volume":"31","author":"Madu","year":"2019","journal-title":"Malawi Med J"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_246_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:18:26Z","timestamp":1787768306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_246_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_246_23","relation":{},"ISSN":["1117-1936","2468-6875"],"issn-type":[{"value":"1117-1936","type":"print"},{"value":"2468-6875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-10-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}